- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07775924
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus (ELIPSI)
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess the Efficacy and Safety of GIA632 in Participants With Moderate to Severe Cutaneous Lichen Planus, Followed by an Extension Period
This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The main purpose of this study is to investigate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP) across a range of dosing regimens and to identify the optimal dosing regimen to be promoted into the confirmatory Phase 3 program.
This study consists of a screening period (up to 4 weeks), a core treatment period (16 weeks double-blind), an extension period (52 weeks), and a safety follow-up period (12 weeks).
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Novartis Pharmaceuticals
- Telefoonnummer: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Studie Contact Back-up
- Naam: Novartis Pharmaceuticals
- Telefoonnummer: +41613241111
- E-mail: novartis.email@novartis.com
Studie Locaties
-
-
New South Wales
-
Sydney, New South Wales, Australië, 2010
- Werving
- Novartis Investigative Site
-
Waitara, New South Wales, Australië, 2077
- Werving
- Novartis Investigative Site
-
-
Victoria
-
Melbourne, Victoria, Australië, 3000
- Werving
- Novartis Investigative Site
-
-
-
-
Ontario
-
London, Ontario, Canada, N6H 5L5
- Werving
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M5A 3R6
- Werving
- Novartis Investigative Site
-
-
-
-
-
Beijing, China, 100050
- Werving
- Novartis Investigative Site
-
Shanghai, China, 200040
- Werving
- Novartis Investigative Site
-
Tianjin, China, 300052
- Werving
- Novartis Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35244
- Werving
- Cahaba Derm and skin hlth ctr 27
-
Hoofdonderzoeker:
- Vlada Groysman
-
Contact:
- Wes Booth
- Telefoonnummer: +1 205 778 1564
- E-mail: wbooth@cahabaderm.com
-
-
California
-
Fountain Valley, California, Verenigde Staten, 92708
- Werving
- First OC Dermatology
-
Hoofdonderzoeker:
- Vivian Laquer
-
Contact:
- Keiry Espinoza
- Telefoonnummer: +1 714 531 2966
- E-mail: kespinoza@dermcaremgt.com
-
-
Florida
-
Hollywood, Florida, Verenigde Staten, 33024
- Werving
- Encore Medical Research
-
Hoofdonderzoeker:
- Jerome Obed
-
Contact:
- Yeniska Hall
- Telefoonnummer: +1 954 400 1725
- E-mail: yhall@encoremedicalresearch.com
-
Miami, Florida, Verenigde Staten, 33173
- Werving
- Miami Derm and Laser Institute
-
Hoofdonderzoeker:
- Jill Waibel
-
Contact:
- Swanee Cepero
- Telefoonnummer: +1 305 279 6060
- E-mail: swaneec@miamidermlaser.com
-
St. Petersburg, Florida, Verenigde Staten, 33714
- Werving
- Global Clinical Professionals
-
Hoofdonderzoeker:
- Wanda M Boote
-
Contact:
- Nailis Echevarria
- Telefoonnummer: +1 727 520 1427
- E-mail: nechevarria@researchgcp.com
-
-
Georgia
-
Macon, Georgia, Verenigde Staten, 31217
- Werving
- Skin Care Physicians Of Georgia
-
Contact:
- Jennifer Smith
- E-mail: jlee@scpog.com
-
Hoofdonderzoeker:
- David J Cohen
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46256
- Werving
- Dawes Fretzin Clinical Rea Group
-
Hoofdonderzoeker:
- Kenneth Dawes
-
Contact:
- Megan Kirchner
- Telefoonnummer: +1 317 516 5030#102
- E-mail: mkirchner@ecommunity.com
-
-
Kansas
-
Overland Park, Kansas, Verenigde Staten, 66213
- Werving
- Essential Medical Research
-
Contact:
- Reena Nagavelli
- Telefoonnummer: 19186451992
- E-mail: ReenaN@emedr.com
-
Hoofdonderzoeker:
- Meena Singh
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- Werving
- Louisiana Dermatology Associates
-
Hoofdonderzoeker:
- Ira Thorla
-
Contact:
- Hilary Kingsley
- Telefoonnummer: +1 225 927 5663
- E-mail: hkingsley@delricht.com
-
New Orleans, Louisiana, Verenigde Staten, 70115
- Werving
- Delricht Research
-
Hoofdonderzoeker:
- Deirdre Hooper
-
Contact:
- Emily Krambeck
- Telefoonnummer: +1 504 336 2667
- E-mail: ekrambeck@delricht.com
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- Uni Of Michigan Health System
-
Contact:
- Hyein Kim
- Telefoonnummer: +1 734 936 5504
- E-mail: kihyein@med.umich.edu
-
Hoofdonderzoeker:
- Mio Nakamura
-
Fort Gratiot, Michigan, Verenigde Staten, 48059
- Werving
- Hamzavi Dermatology
-
Hoofdonderzoeker:
- Iltefat Hamzavi
-
Contact:
- Brynn Bemis
- Telefoonnummer: +1 810 455 1600
- E-mail: bbemis@hamzavi.com
-
-
Minnesota
-
New Brighton, Minnesota, Verenigde Staten, 55112
- Werving
- Minnesota Clinical Study Center
-
Contact:
- Madeline Thompson
- Telefoonnummer: +1 763 576 9312
- E-mail: mthompson@associatedskincare.com
-
Hoofdonderzoeker:
- Steven E Kempers
-
-
Missouri
-
Saint Joseph, Missouri, Verenigde Staten, 64506
- Werving
- MediSearch Clinical Trials
-
Contact:
- Heather Jackson
- Telefoonnummer: 816 364 1515
- E-mail: heather.jackson@medisearchderma.com
-
Hoofdonderzoeker:
- Melody Stone
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68144
- Werving
- Skin Specialists PC
-
Hoofdonderzoeker:
- Joel Schlessinger
-
Contact:
- Carrie Hill
- Telefoonnummer: +1 402 334 7546
- E-mail: carrie@lovelyskin.com
-
-
Texas
-
Bellaire, Texas, Verenigde Staten, 77401
- Werving
- Bellaire Dermatology Associates
-
Hoofdonderzoeker:
- Craig F Teller
-
Contact:
- Hannah Green
- Telefoonnummer: +1 713 661 4383
- E-mail: hannah.green@bellairedermatology.com
-
Mansfield, Texas, Verenigde Staten, 76063
- Werving
- NextGen Clinical Research and Innovation Inc-Network
-
Hoofdonderzoeker:
- Jeannine Hoang
-
Contact:
- Lakkureddi Alagarsamy
- E-mail: LakkureddiA@NextGenClinical.Us
-
Pflugerville, Texas, Verenigde Staten, 78660
- Werving
- Austin Inst for Clinical Research
-
Hoofdonderzoeker:
- Edward Lain
-
Contact:
- Dominique Talamantes
- Telefoonnummer: +1 512 279 2545
- E-mail: d.talamantes@atxresearch.com
-
San Antonio, Texas, Verenigde Staten, 78213
- Werving
- RFSA Dermatology
-
Hoofdonderzoeker:
- Lindsey Finklea
-
Contact:
- Jonathan Joseph
- E-mail: jonathanj.rfsadermatology@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Male or female (as assigned at birth) participants ≥ 18 years of age at the time of screening.
- Individuals with a diagnosis of cLP, confirmed
- histologically by a skin biopsy (either historically within 1 year prior to screening or at screening if historical one not available), and
- by physical examination by the investigator at screening.
- Moderate to severe cLP
- Two or more body regions affected (any two or more of the following: head and neck, trunk, upper extremities including hands, lower extremities including feet).
- Diagnosis of cLP inadequately controlled by at least one topical treatment for at least 3 months (either via continuous use or burst and taper regimen), or such treatment being considered not advisable, as per investigator judgement, assessed at screening.
Topical treatment includes, but is not limited to, topical corticosteroids, topical calcineurin inhibitors, topical cholecalciferol analogues, topical PDE4 inhibitors, topical JAK inhibitors, and topical aryl hydrocarbon receptor agonists.
Key Exclusion Criteria:
- Individuals unable or unwilling to follow the study procedures, handle the electronic diary (eDiary), and/or to complete the study-related questionnaires.
- Diagnosis of drug-induced lichen planus (lichenoid drug eruption) or lichen planus pigmentosus.
- Presence of skin conditions that may interfere with study assessments, including histologic findings in the biopsy, as assessed at screening and baseline.
- Previous exposure to biologic drugs directly targeting IL-15 or any subunit of the IL-15 receptor.
- Use of prohibited medication and treatments.
Other protocol-defined inclusion/exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
Participants will receive matching placebo according to the treatment regimen assigned at randomization during the study treatment period. |
Matching placebo GIA632 administered according to the assigned study treatment regimen. |
|
Experimenteel: GIA632 - Treatment regimen 1
Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. |
GIA632 administered according to the assigned study treatment regimen. |
|
Experimenteel: GIA632 - Treatment regimen 2
Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. |
GIA632 administered according to the assigned study treatment regimen. |
|
Experimenteel: GIA632 - Treatment regimen 3
Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. |
GIA632 administered according to the assigned study treatment regimen. |
|
Experimenteel: GIA632 - Treatment regimen 4
Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. |
GIA632 administered according to the assigned study treatment regimen. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants achieving an Investigator Global Assessment (IGA) response
Tijdsspanne: Week 16
|
IGA response is defined as an Investigator Global Assessment score of 0 (clear) or 1 (almost clear). The IGA is measured on a 5-point scale ranging from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. |
Week 16
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Absolute change from baseline in weekly mean daily Peak Pruritus Numerical Rating Scale (PP-NRS) score
Tijdsspanne: Baseline and Week 16
|
The Peak Pruritus Numerical Rating Scale (PP-NRS) is used to assess participant-reported intensity of worst itch during the previous 24 hours. Participants rate their worst itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). |
Baseline and Week 16
|
|
Number of participants achieving an IGA score of Clear (0) or Almost Clear (1)
Tijdsspanne: Weeks 4, 8, and 12
|
The IGA is measured on a 5-point scale ranging from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. |
Weeks 4, 8, and 12
|
|
Number of participants achieving a ≥2-Point improvement from baseline in IGA score
Tijdsspanne: Baseline, Weeks 4, 8, 12, and 16
|
The IGA is measured on a 5-point scale ranging from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. |
Baseline, Weeks 4, 8, 12, and 16
|
|
Absolute change from baseline in Lichen Planus Activity and Damage Index (LiPADI) Activity score
Tijdsspanne: Baseline, Weeks 4, 8, 12, and 16
|
The Lichen Planus Activity and Damage Index (LiPADI) is a clinical assessment tool used to evaluate the severity and extent of lichen planus. The activity score assesses active inflammation based on morphologic features including erythema, hypertrophy, and scaling. |
Baseline, Weeks 4, 8, 12, and 16
|
|
Absolute Change From Baseline in Lichen Planus Activity and Damage Index (LiPADI) Damage Score
Tijdsspanne: Baseline, Weeks 4, 8, 12, and 16
|
The Lichen Planus Activity and Damage Index (LiPADI) is a clinical assessment tool used to evaluate the severity and extent of lichen planus. The damage score assesses disease-related damage based on morphologic features including hyperpigmentation and scarring/atrophy. |
Baseline, Weeks 4, 8, 12, and 16
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Up to 80 weeks
|
Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs. |
Up to 80 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CGIA632C12201
- 2025-522300-25-00 (Andere identificatie: EU CTIS)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .